CI & Patent News: 22/11/2010


1) Paragraph IV Litigation: Impax Confirms Patent Challenge Relating to WELCHOL® (Colesevelam HCl) for Oral Suspension, 3.75 gm/packet and 1.875 gm/packet (Link).

Colesevelam is bile acid sequestrant.  Genzyme is originator for Colesevelam and is marketed by Daiichi sankyo in USA. Colesevelam is co polymer of three distinct monomers. Ten patents are listed from two INPADOC family. Nine patents among 10 are single family and expires end of 2014 and the 10th patent 7229613 expires on Oct 17, 2022.  Complaint details will be updated as soon as i get it.

2) f-star and Boehringer Ingelheim to Collaborate in Discovery and Development of Therapeutic Antibodies  (Link)

3) Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta® (duloxetine hydrochloride) Delayed-Release 20, 30 and 60 mg Capsules

4) The UK appeals Court upheld valid claims of two KCI patents (order). In this decision, Validity of claims of EP0777504B1 & EP0853950B1 patents are upheld and held Smith & Nephew’s Negative pressure wound therapy (NPWT) apparatus would infringe claims of ‘504 & 395. KCI offers vaccum assited closure therapy (V.A.C.® Therapy).

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news and tagged , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s